Relationship between uric acid and sarcopenia in middle-aged and aged men with type 2 diabetes mellitus

doi:10.3969/j.issn.1006-7795.2021.03.019

Abstract

Abstract: Objective To explore the relationship between uric acid (UA) and sarcopenia in middle-aged and aged men with type 2 diabetes (T2DM). Methods All 275 men with T2DM aged over 55 years were selected from the Department of Endocrinology of Xuanwu Hospital. The uric acid (UA), 25 hydroxyvitamin D₃ (25OHD₃), hemoglobin A1c (HbA1c) were measured. The appendicular skeletal muscle mass (ASM), grip strength and gait speed were assessed. In addition, appendicular skeletal muscle mass index (ASMI) was calculated. The association between uric acid and sarcopenia was assessed. Results The prevalence of sarcopenia in men aged over 55 years with T2DM was 32.73%, the level of uric acid in participants of the sarcopenia group was significantly lower than that in non-sarcopenia group [(307.5±76.57) mmol/L vs (342.02±89.02) mmol/L, P=0.002)]. Pearson correlation analysis showed that UA was significantly positively correlated with ASMI (r=0.201, P=0.006), and UA was not significantly correlated with grip strength and gait speed (P>0.05). Multivariate logistic regression analysis showed uric acid was an independent protective factor for sarcopenia in middle-aged and aged men with T2DM (OR=0.89,95%CI:0.79-0.97,P=0.043). Conclusion Uric acid plays a protective role in sarcopenia in middle-aged and aged men with T2DM.

Key words: type 2 diabetes mellitus (T2DM), uric acid, sarcopenia, muscle mass

CLC Number:

R587.1

Mi Yingxin, Wang Xin, Zhang Kai, Li Keyue, Sun Lina, Xiu Shuangling. Relationship between uric acid and sarcopenia in middle-aged and aged men with type 2 diabetes mellitus[J]. Journal of Capital Medical University, 2021, 42(3): 453-458.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2021.03.019

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2021/V42/I3/453

References

[1] 吴佳佳,邢学农.肌少症研究进展[J].医学综述,2016,22(4):753-756.
[2] Budui S L, Rossi A P, Zamboni M.The pathogenetic bases of sarcopenia[J].Clin Cases Miner Bone Metab,2015,12(1):22-26.
[3] 王宇,姜明霞,许琦,等.肌少症与代谢危险因素的相关性研究[J].医学研究生学报, 2017,30(2):181-185.
[4] Anagnostis P, Gkekas N K, Achilla C, et al. Type 2 diabetes mellitus is associated with increased risk of sarcopenia:a systematic review and Meta-analysis[EB/OL].(2020-08-09)[2020-09-07].https://doi.org/10.1007/s00223-020-00742-y.
[5] Cui M, Gang X, Wang G, et al. A cross-sectional study:associations between sarcopenia and clinical characteristics of patients with type 2 diabetes[J].Medicine (Baltimore),2020,99(2):e18708.
[6] Sazlina S G, Lee P Y, Chan Y M, et al. The prevalence and factors associated with sarcopenia among community living elderly with type 2 diabetes mellitus in primary care clinics in malaysia[J]. PLoS One,2020,15(5):e0233299.
[7] 刘青,江力勤,赵圣刚.高尿酸血症的氧化应激反应与心血管疾病的关系[J].临床医药文献杂志,2018,5(91):193-194.
[8] 罗鸿宇,华琦,刘荣坤.室性期前收缩患者左室质量指数与早搏负荷、血尿酸的相关性分析[J].首都医科大学学报,2019,40(3):374-378.
[9] 韩玉梅,陈硕,丁然,等.北京市体检人群血尿酸增高率及相关因素分析[J].首都医科大学学报,2015,36(2):303-307.
[10] 孙海斌.尿酸减轻氧化应激诱导的血管内皮细胞损伤[J].中国动脉硬化杂志,2014,22(10):1019-1022.
[11] Alberti K G, Zimmet P Z.Definition, diagnosis and classification of diabetes mellitus and its complications.Part 1:diagnosis and classification of diabetes mellitus provisional report of a WHO consultation[J].Diabet Med,1998,15(7):539-553.
[12] Baumgartner R N, Koehler K M, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico[J].Am J Epidemiol,1998,147(8):755-763.
[13] Mesinovic J, Zengin A, De Courten B, et al. Sarcopenia and type 2 diabetes mellitus:a bidirectional relationship[J].Diabetes Metab Syndr Obes,2019(12):1057-1072.
[14] Beavers K M, Beavers D P, Serra M C, et al. Low relative skeletal muscle mass indicative of sarcopenia is associated with elevations in serum uric acid levels:findings from NHANES III[J]. J Nutr Health Aging,2009,13(3):177-182.
[15] Ferrando B, Olaso-Gonzalez G, Sebastia V, et al.Allopurinol and its role in the treatment of sarcopenia[J].Rev Esp Geriatr Gerontol,2014,49(6):292-298.
[16] Xu Z R, Zhang Q, Chen L F, et al.Characteristics of hyperuricemia in older adults in China and possible associations with sarcopenia[J].Aging Med (Milton),2018,1(1):23-34.
[17] Dong X W, Tian H Y, He J, et al. Elevated serum uric acid is associated with greater bone mineral density and skeletal muscle mass in middle-aged and older adults[J].PLoS One,2016,11(5):e0154692.
[18] Kang D H, Ha S K.Uric acid puzzle:dual role as anti-oxidantand pro-oxidant[J].Electrolyte Blood Press,2014,12(1):1-6.
[19] Marzetti E, Calvani R, Tosato M, et al.Sarcopenia:an overview[J].Aging Clin Exp Res,2017,29(1):11-17.
[20] Macchi C, Molino-Lova R, Polcaro P, et al.Higher circulating levels of uric acid are prospectively associated with better muscle function in older persons[J]. Mech Ageing Dev, 2008,129(9):522-527.
[21] Molino-Lova R, Sofi F, Pasquini G, et al.Higher uric acid serum levels are associated with better muscle function in the oldest old:Results from the Mugello Study[J]. Eur J Intern Med, 2017 ,41:39-43.
[22] Lytvyn Y, Perkins B A, Cherney D Z.Uric acid as a biomarker and a therapeutic target in diabetes[J].Can J Diabetes,2015,39(3):239-246.
[23] Li G X, Jiao X H, Cheng X B.Correlations between blood uric acid and the incidence and progression of type 2 diabetes nephropathy[J].Eur Rev Med Pharmacol Sci,2018,22(2):506-511.
[24] Yu S, Chen Y, Hou X, et al.Serum uric acid levels and diabetic peripheral neuropathy in type 2 diabetes:a systematic review and meta-analysis[J].Mol Neurobiol,2016,53(2):1045-1051.
[25] Xiong Q, Liu J, Xu Y. Effects of uric acid on diabetes mellitus and its chronic complications[EB/OL].(2019-10-13)[2020-09-07].https://doi.org/10.1155/2019/9691345.
[26] Grimby G, Saltin B.The ageing muscle[J]. Clin Physiol, 1983,3(3):209-218.
[27] Flakoll P, Sharp R, Baier S, et al.Effect of beta-hydroxy-beta-methylbutyrate, arginine, and lysine supplementation on strength, functionality, body composition, and protein metabolism in elderly women[J].Nutrition,2004,20(5):445-451.
[28] Baier S, Johannsen D, Abumrad N, et al.Year-long changes in protein metabolism in elderly men and women supplemented with a nutrition cocktail of beta-hydroxy-beta-methylbutyrate (HMB), L-arginine, and L-lysine[J]. JPEN J Parenter Enteral Nutr,2009,33(1):71-82.
[29] Janssen I, Heymsfield S B, Wang Z M, et al. Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr[J].J Appl Physiol (1985), 2000,89(1):81-88.
[30] Bianchi L, Abete P, Bellelli G, et al.Prevalence and clinical correlates of sarcopenia, identified according to the EWGSOP definition and diagnostic algorithm, in hospitalized older people:The GLISTEN Study[J]. J Gerontol A Biol Sci Med Sci,2017,72(11):1575-1581.
[31] Fukuoka Y, Narita T, Fujita H, et al. Importance of physical evaluation using skeletal muscle mass index and body fat percentage to prevent sarcopenia in elderly Japanese diabetes patients[J].J Diabetes Investig,2019,10(2):322-330.
[32] Nasimi N, Dabbaghmanesh M H, Sohrabi Z. Nutritional status and body fat mass:determinants of sarcopenia in community-dwelling older adults[J]. Exp Gerontol, 2019,122:67-73.
[33] Kalinkovich A, Livshits G.Sarcopenic obesity or obese sarcopenia:A cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis[J].Aging Res Rev,2017, 35:200-221.
[34] Cruz-Jentoft A J, Kiesswetter E, Drey M, et al. Nutrition, frailty, and sarcopenia[J]. Aging Clin Exp Res,2017,29(1):43-48.